Loading market data...
Fri, 30 Oct 2026
06:58:26 am
Fri, 30 Oct 2026
06:58:26 am
Rudransh Sangwan
Published at: October 30, 2026, 4:04 AM
Synopsis
Alivus Life Sciences Q2 FY27 results show net profit rising 51.3% to ₹196.8 crore, revenue growing 16% to ₹682 crore and EBITDA margin reaching 38.88%.
Alivus Life Sciences reported a 51.3% year-on-year increase in net profit to ₹196.8 crore in Q2 FY27. Revenue from operations rose 16% to ₹682 crore, while the EBITDA margin expanded to 38.88% from 30.46% a year earlier.
| Financial Metric | Q2 FY27 | Year-on-Year Change |
|---|---|---|
| Revenue | ₹682 crore | +16% |
| EBITDA | ₹265 crore | Margin at 38.88% |
| Net Profit | ₹196.8 crore | +51.3% |
| Free Cash Flow | ₹270.2 crore | — |
The company's non-GPL business grew 20.8%, contributing 79% of revenue. Its contract development and manufacturing organisation (CDMO) business increased 79.9% to ₹50 crore, while the Generic API segment grew 11%.
Alivus served customers across major global markets, with regulated markets accounting for 85% of Q2 revenue.
As of September 30, 2026, Alivus held ₹1,011.6 crore in cash and cash equivalents, including short-term investments, and reported strong quarterly free cash flow of ₹270.2 crore.
The company is expanding manufacturing capacity through projects in Solapur, Ankleshwar and Dahej, while developing a new research and development facility in Taloja.
| Period | Return |
|---|---|
| 1 day | +6.68% |
| 5 days | +9.93% |
| 1 month | +2.82% |
| 6 months | +38.74% |
| 1 year | +53.63% |
| 5 years | +120.59% |
Key takeaway: Alivus Life Sciences delivered strong profit growth and improved margins in Q2 FY27, supported by non-GPL business growth and higher CDMO revenue.
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
Motilal Oswal Q2 FY27 results show net profit rising 198% to ₹1,080 crore, revenue increasing 64% to ₹3,040 crore and EBITDA margin reaching 60.37%.
Bliss GVS Pharma Q2 FY27 results show revenue rising 37.3% to ₹261.13 crore, EBITDA jumping 161.4% and net profit increasing 196%.
Thyrocare Q2 FY27 revenue rose 25.1% to ₹270.81 crore, while net profit fell 66.9% to ₹15.89 crore amid a ₹44.98 crore impairment loss.
Patel Retail will invest ₹2 crore to add 20,000 sq ft to its Ambernath distribution centre, increasing covered area to 84,000 sq ft.
Shadowfax Technologies Q2 FY27 results show revenue growth of 56.6% to ₹1,537.70 crore and a 422% jump in net profit to ₹67.95 crore.
